Moleculin Biotech ( (MBRX) ) just unveiled an update.
On May 6, 2025, Moleculin Biotech announced that the World Health Organization’s INN Expert Committee approved ‘naxtarubicin’ as the non-proprietary name for Annamycin, a next-generation anthracycline in development. This approval marks a significant step in Annamycin’s development and potential commercialization, as it is currently undergoing a pivotal Phase 3 clinical trial for treating relapsed or refractory acute myeloid leukemia, with interim data expected in the second half of 2025.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viral infections. Its lead program, Annamycin, is a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, with a focus on avoiding multidrug resistance and cardiotoxicity.
Average Trading Volume: 5,869,426
Technical Sentiment Signal: Sell
Current Market Cap: $14.55M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.